

Specimen Requisition Lab Ref No

**Collected Date Received Date** 

Legend

**Result Value Colors** 



Result is within the clinical reference range

Result Value Labels



Below Low Normal

Result Value Reference Range Lab

## Metabolic & Endocrine Health

## Thyroid

### T3 Reverse (RT3), LC/MS/MS

T3 REVERSE, LC/MS/MS	<b>21</b> 02/22/22	8-25 ng/dL	AMD
Comments	characteristics hav Diagnostics Nichols not been cleared or Administration. Thi	coped and its analytical performance been determined by Quest Institute Chantilly, VA. It has approved by the U.S. Food and Drugs assay has been validated pursuantions and is used for clinical	3

#### T3 Total

T3, TOTAL	127	76-181 ng/dL	MI
	02/22/22		

### T3 Uptake

T3 UPTAKE	27	22-35 %	MI
	02/22/22		

#### T3, Free



Result	Value	Reference Range	Lab
T3, FREE	<b>2.9</b> 02/22/22	2.3-4.2 pg/mL	MI
T4 (Thyroxine), Total			
T4 (THYROXINE), TOTAL	10.3 02/22/22	5.1-11.9 mcg/dL	MI
FREE T4 INDEX (T7)	<b>2.8</b> 02/22/22	1.4-3.8	MI
T4, Free			
T4, FREE	<b>1.3</b> 02/22/22	0.8-1.8 ng/dL	MI
TSH			
TSH	1.47 02/22/22	mIU/L	MI
Comments	Reference Range		
	> or = 20 Years 0	.40-4.50	
	Pregnancy Ran	ges	
	First trimester	0.26-2.66	
	Second trimester Third trimester	0.55-2.73 0.43-2.91	
Metabolic Hormones			
Growth Hormone (GH)			
GROWTH HORMONE (GH)	<b>0.1</b> 02/22/22	< OR = 7.1 ng/mL	TP
Comments	Because of a pulsatile secret (unstimulated) growth hormony frequently undetectable in and are not reliable for dia Regarding suppression tests is diagnostic of acromegaly  Typical GH response in health Using the glucose tolerance acromegaly is ruled out its	ne (GH) levels are normal children and adults agnosing GH deficiency. , failure to suppress GH .  thy subjects: ce (GH suppression) test,	

is <1.0 ng/mL at any point in the timed sequence. [Katznelson L, Laws Jr ER, Melmed S, et al.

Acromegaly: an Endocrine Society Clinical Practice



Result	Value	Reference Range	Lab
	Guideline. J Clin : 3951].	Endocrinol Metab 2014; 99: 3933-	
	Using GH stimulation	on testing, the following result	
	at any point in the	e timed sequence makes GH	
	deficiency unlikel	y:	
	Adults ( $>$ or = 20	years):	
	Insulin Hypogly	rcemia > or = 5.1 ng/mL	
	Arginine/GHRH	> or = 4.1 ng/mL	
	Glucagon	> or = 3.0 ng/mL	
	Children (< 20 yea	ars):	
	All Stimulation Tests > or = 10.0 ng/mL		

### IGF-I, LC/MS

IGF 1, LC/MS	143 02/22/22	52-328 ng/mL	EZ
Z SCORE (FEMALE)	0.0 02/22/22	-2.0 - +2.0 SD	EZ
Comments	characteristics have Nichols Institute San cleared or approved b	ed and its analytical performance been determined by Quest Diagnostic Juan Capistrano. It has not been y FDA. This assay has been validate regulations and is used for clinical	ed.

# Reproductive Hormones

### DHEA Sulfate, Immunoassay

DHEA SULFATE	8 L 02/22/22	15-205 mcg/dL	МІ
Comments	DHEA-S values fall with advanction reference, the reference is old patients are:		
	Male: 93-415 mcg/dL Female: 19-237 mcg/dL		

### Estradiol

ESTRADIOL	<15 02/22/22	pg/mL	MI
Comments	Reference Range		
	Follicular Phase:	19-144	
	Mid-Cycle:	64-357	
	Luteal Phase:	56-214	
	Postmenopausal:	< or = 31	



Result	Value	Reference Range	Lab
	Reference range established on population. No pre-pubertal reestablished using this assay. whom low Estradiol levels are pre-pubertal children and hypofemales), the Quest Diagnostic Estradiol, Ultrasensitive, LCM (order code 30289).	ference range For any patients for anticipated (e.g. males, gonadal/post-menopausal s Nichols Institute	
	Please note: patients being tr fulvestrant (Faslodex(R)) have interference in immunoassay me measurement. The cross reactiv elevated estradiol test result inappropriate clinical assessm Quest Diagnostics order code 3 Ultrasensitive LC/MS/MS demons	thods for estradiol ity could lead to falsely s leading to an lent of estrogen status.	

### Estrogen, Total, Serum

ESTROGEN, TOTAL, SERUM	317.3 02/22/22	pg/mL	EZ
Comments	Reference Ranges for Total Es	trogen:	
	Follicular Phase (1-12 days): 90-590 pg Luteal Phase: 130-460 pg Postmenopausal: 50-170 pg	g/mL	
	The total estrogen assay is n pre-pubertal children.	ot recommended for use in	

reactivity with fulvestrant.

#### FSH and LH

FSH	<b>45.7</b> 02/22/22	mIU/mL	MI
Comments	Reference Range		
	Follicular Phase	2.5-10.2	
	Mid-cycle Peak	3.1-17.7	
	Luteal Phase	1.5- 9.1	
	Postmenopausal	23.0-116.3	
LH	32.0	mIU/mL	MI
	02/22/22		

Comments Reference Range

Follicular Phase 1.9-12.5



Result	Value		Reference Range	Lab
	Mid-Cycle Peak	8.7-76.3		
	Luteal Phase	0.5-16.9		
	Postmenopausal	10.0-54.7		

## Progesterone, Immunoassay

PROGESTERONE	<b>&lt;0.5</b> 02/22/22	ng/mL	MI
Comments	Reference Ranges		
	Female		
	Follicular Phase	e < 1.0	
	Luteal Phase	2.6-21.5	
	Post menopausal	< 0.5	
	Pregnancy		
	1st Trimester	4.1-34.0	
	2nd Trimester	24.0-76.0	
	3rd Trimester	52.0-302.0	

### Testosterone, Total And Free And Sex Hormone Binding Globulin

TESTOSTERONE, TOTAL, MS	3 02/22/22	2-45 ng/dL	AMD
Comments	http://education. TotalTestosterone	ng provided for informational/	
	This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.		
TESTOSTERONE, FREE	<b>0.4</b> 02/22/22	0.1-6.4 pg/mL	AMD
Comments	characteristics h Diagnostics Nicho not been cleared Administration. T	This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.	
SEX HORMONE BINDING GLOBULIN	<b>45</b> 02/22/22	17-124 nmol/L	AMD



Result Value Reference Range Lab

## Other

### Other

#### Pregnenolone, LC/MS/MS

PREGNENOLONE, LC/MS 29 02/22/22

22-237 ng/dL

ΕZ

#### Comments

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.